What's bs is the company making investors guess all these years for no good reason, if your version is true. They clearly go out of their way never to mention the enrollment halt for whatever purpose that serves them.
Years ago I had heard the FDA halt was tied to the study group and compassionate use, that they were forwarding too many patients to those groups. But I also read it was due to poor PFS stats, which we've now seen whether due to pseudo or not. Whatever it is there's just no denying the inclusion criteria for the trial was especially narrow.
You can't have it both ways. They chose to prioritize those with near total resection and specific brain region so as to provide longer survival for PFS monitoring. Otherwise they would've just accepted nearly all stages and conditions.
Market Data 
Markets 
AI
